Journal profile · Cell Biology
Cell Stem Cell
ISSN 1934-5909 · eISSN 1875-9777 · Cell Press · UNITED STATES · Monthly · Founded 2007
Cell Stem Cell: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 23.06; hybrid open access; APC about USD 10,400; median 187 days to acceptance (95 articles, last 24 months); community-reported acceptance: about 20%; 161 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cell Stem Cell is published by Cell Press and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Pluripotent Stem Cells Research, CRISPR and Genetic Engineering and Epigenetics and DNA Methylation, together about 39.1% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Cell Stem Cell Cell Stem Cell is a broad-spectrum journal that covers the entire spectrum of stem cell biology. Topics covered include embryonic stem cells, pluripotency, germline stem cells, tissue-specific stem cells, stem cell differentiation, epigenetics, stem cell genomics and systems biology, genome reprogramming, cancer stem cells, stem cell niches, stem-cell-based disease models, nuclear transfer technology, bioengineering, drug discovery, in vivo imaging of stem cells, therapeutic applications, regenerative medicine, clinical and translational insights, stem cell research policies, ethical issues, and technical or resource-based innovations. More This journal offers the option to publish open access Authors may choose to publish open access by paying an article publishing charge. Article publishing charge: $10,400 To provide gold open access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published open access
From the journal's Aims & Scope
Research area (LetPub): Cell Biology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Pluripotent Stem Cells ResearchBiochemistry, Genetics and Molecular Biology22%
- CRISPR and Genetic EngineeringBiochemistry, Genetics and Molecular Biology11.2%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology6%
- Biomedical Ethics and RegulationMedicine5.3%
- Cancer Cells and MetastasisMedicine5.1%
- Neurogenesis and neuroplasticity mechanismsNeuroscience4.5%
- Hematopoietic Stem Cell TransplantationMedicine4.2%
- Renal and related cancersBiochemistry, Genetics and Molecular Biology4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Cell & Tissue Engineering | Zone 1 |
| Minor | Cell Biology | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Cell & Tissue Engineering | Zone 1 |
| Minor | Cell Biology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Cell & Tissue Engineering | Zone 1 |
| Minor | Cell Biology | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 23.06LetPub ·
- Impact factor (publisher)
- 23.3Publisher website ·
- CiteScore 2026-06
- 36.1LetPub ·
- CiteScore (publisher)
- 36.1Publisher website ·
- SJR 2026-06
- 12LetPub ·
- SNIP 2026-06
- 4.33LetPub ·
- h-index
- 212LetPub ·
- h-index
- 379OpenAlex ·
- i10-index
- 2,594OpenAlex ·
- 2-year mean citedness
- 19.48OpenAlex ·
- Self-citation rate
- 3%LetPub ·
- Share of gold OA articles
- 39.48%LetPub ·
Volume
- Articles per year
- 107LetPub ·
Articles by year OpenAlex count · 3,856 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 133 | 60 | 292 |
| 2025 | 161 | 99 | 2,242 |
| 2024 | 175 | 175 | 6,601 |
| 2023 | 155 | 155 | 7,666 |
| 2022 | 153 | 153 | 11,121 |
| 2021 | 199 | 197 | 16,670 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
187 daysMedian, submission to acceptance · P25–P75 29 days – 286 days
- Acceptance to online
- median 25 days (63 articles)
- Submission to online
- median 270 days
- Sample
- 95 articles with submission and acceptance dates (348 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1 monthLetPub ·
- Average acceptance (community reports)
- 20%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 10,400 / EUR 9,640 / GBP 8,330 / JPY 1,289,910 | — | — | |
| Publisher website | USD 10,400 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Cell Press
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 2007
- ISSN
- 1934-5909
- Electronic ISSN
- 1875-9777
- Latest issue on the website
- Volume 33, Issue 9 (September 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Cell Stem Cell
What CAS zone is Cell Stem Cell in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cell Stem Cell is in Zone 1 of Medicine, and in Zone 1 of the minor category Cell & Tissue Engineering / Cell Biology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cell Stem Cell?
The latest impact factor listed by LetPub is 23.06; CiteScore 36.1, h-index 379.
How long does peer review take at Cell Stem Cell?
Based on the dates recorded on 95 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 187 days (interquartile range 29–286 days); authors report an average review time of about 1 month; the community-reported acceptance is “about 20%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Cell Stem Cell?
According to LetPub and DOAJ records, Cell Stem Cell is indexed in SCIE and Scopus.
Is Cell Stem Cell open access, and what is the APC?
Cell Stem Cell is a hybrid journal. For open-access publication: APC about USD 10,400.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .